Tisotumab Vedotin Plus Carboplatin, Pembrolizumab, or Bevacizumab for Recurrent or Metastatic Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
J. Clin. Oncol 2023 Aug 31;[EPub Ahead of Print], I Vergote, E Van Nieuwenhuysen, RE O'Cearbhaill, A Westermann, D Lorusso, S Ghamande, DC Collins, S Banerjee, CA Mathews, C Gennigens, D Cibula, KS Tewari, K Madsen, F Köse, AL Jackson, IA Boere, G Scambia, LM Randall, A Sadozye, JF Baurain, E Gort, M Zikán, HG Denys, N Ottevanger, F Forget, C Mondrup Andreassen, L Eaton, MJ Chisamore, L Viana Nicacio, I Soumaoro, BJ MonkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.